登录新浪财经APP 搜索【信披】查看更多考评等级 控股股东宁波美诺华控股集团有限公司及其一致行动人姚成志保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： ● 经中国证券登记结算有限责任公司上海分公司确认，宁波美诺华药业股份有限公司(以下简称"公司") 回购注销2024年限制性股票激励计划部分股份事宜已于2026年2月12日办理完成，本次回购股份注销完 成后，公司总股本由220,631,264股变更为220,450,164股。 ● 本次回购注销完成后，公司控股股东宁波美诺华控股集团有限公司、实际控制人姚成志先生持有公司 的股份数量不变的情况下，合计持有公司股份比例由25.9963%被动增加至26.0176%，适用权益变动触 及1%整数倍的情形。本次权益变动不会导致公司控股股东及实际控制人发生变化。 ■ 一、信息披露义务人及其一致行动人的基本信息 1、身份类别 公司本次回购注销2024年限制性股票激励计划股份数量为181,100股。经中国证券登记结算有限责任公 司上海分公司确认，回购注销2024年限制性股票激励计划部分股份事宜已于2026年2月12日办理完成。 本次回 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ● 本次回购注销完成后，公司控股股东宁波美诺华控股集团有限公司、实际控制人姚成志先生持有公司 的股份数量不变的情况下，合计持有公司股份比例由25.9963%被动增加至26.0176%，适用权益变动触 及1%整数倍的情形。本次权益变动不会导致公司控股股东及实际控制人发生变化。 ■ 证券代码：603538 证券简称：美诺华 公告编号：2026-020 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于回购股份注销完成暨持股5%以上股东权益 被动变动触及1%整数倍的提示性公告 控股股东宁波美诺华控股集团有限公司及其一致行动人姚成志保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 经中国证券登记结算有限责任公司上海分公司确认，宁波美诺华药业股份有限公司(以下简称"公司") 回购注销2024年限制性股票激励计划部分股份事宜已于2026年2月12日办理完成，本次回购股份注销完 成后，公司总股本由220,631,264股变更为220 ...

| | | 宁波美诺华药业股份有限公司 关于回购股份注销完成暨持股 5%以上股东权益 被动变动触及 1%整数倍的提示性公告 控股股东宁波美诺华控股集团有限公司及其一致行动人姚成志保证向本公司提供的 信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加√ | | 比例减少□ | | --- | --- | --- | --- | | 权益变动前合计比例 | 25.9963% | | | | 权益变动后合计比例 | 26.0176% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否√ | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、信息披露义务人及其一致行动人的基本信息 1、身份类别 1 经中国证券登记结算有限责任公司上海分公司确认，宁波美诺华药业股份有 限公司(以下简称"公司")回购注销 2024 年限制性股票激励计划部分股份 事宜已于 2026 年 2 月 12 日办理完成，本次回购股份注销完成后，公司总股 本由 220,631,264 股 ...

美诺华公告，公司回购注销2024年限制性股票激励计划部分股份事宜已于2026年2月12日办理完成，本 次回购股份注销完成后，公司总股本由2.21亿股变更为2.2亿股。公司控股股东宁波美诺华控股集团有限 公司、实际控制人姚成志先生持有公司的股份数量不变的情况下，合计持有公司股份比例由25.9963% 被动增加至26.0176%。本次权益变动不会导致公司控股股东及实际控制人发生变化。 ...

Group 1 - Core viewpoint: Meinuo Pharma (603538) announced that its wholly-owned subsidiary, Meinuo Tiankang, is participating in the national centralized procurement bidding, with ten products including Perindopril tert-butylamine tablets expected to be selected, covering cardiovascular and anti-infection fields [1] - Expected sales: The total sales for the first three quarters of 2025 are projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue during the same period [1] - Implementation timeline: The selection results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] Group 2 - Recent stock performance: Over the past seven trading days (from February 6 to February 13, 2026), Meinuo's stock price fluctuated within a range of 4.90%, with the latest closing price at 21.18 yuan, reflecting a slight increase of 0.76% compared to February 6 [2] - Capital flow: On February 13, the net outflow of main funds was 2.2299 million yuan, while retail funds saw a net inflow; the turnover rate remained stable between 1% and 3% [2] - Market comparison: The overall performance of Meinuo was slightly better than the chemical pharmaceutical sector, which saw a decline of 0.97%, but weaker than the overall market index [2]

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products including Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets expected to be selected for this procurement [1]. Group 1: Proposed Selected Products - The ten proposed selected products are expected to generate a total sales revenue of 71.75 million yuan in the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1]. - The number of proposed selected products represents 40% of the total number of formulations in the company's formulation segment [1]. Group 2: Impact on the Company - The results of the procurement are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of the selected drugs during the procurement cycle [1]. - The procurement cycle for the selected drugs will last until December 31, 2028, starting from the actual execution date of the selection results [1].

二、 对公司的影响 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-019 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于全资子公司参与国家组织集采药品协议期满品种接续采购 拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，宁波美诺华药业股份有限公司（以下简称"公司"）的全资子公司宁 波美诺华天康药业有限公司（以下简称"美诺华天康"）参加了国家组织集采药 品协议期满品种接续采购办公室组织的国家组织集采药品协议期满品种接续采 购的投标工作, 培哚普利叔丁胺片、硫酸氢氯吡格雷片、恩格列净片等十个品种 拟中选本次接续采购。现将相关情况公告如下: | 序号 | 拟中选企业 | 品种名称 | 适应症或功能主治 用于以下患者，预防动脉粥样硬化血栓形成事件： | | --- | --- | --- | --- | | | | | •近期心肌梗死患者（从几天到小于 35 天），近期缺血性 卒中患者（从 7 ...

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] - The procurement is part of the continuation of the national centralized procurement for drugs from batches 1-8, with results expected to be implemented by the end of March 2026 [1] Group 2: Financial Impact - The total sales for the ten selected products are projected to be 71.75 million yuan for the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1] - The number of selected products represents 40% of the total products in the formulation segment of the company [1] Group 3: Procurement Cycle - The procurement cycle for the selected drugs will run from the actual execution date of the selection results until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle and ensure the completion of the agreed procurement volume [1]

Core Viewpoint - Meinuo Pharma's wholly-owned subsidiary, Meinuo TianKang, is participating in the national organized procurement for drugs, with 10 products, including Perindopril tert-butylamine tablets, expected to be selected for procurement [1] Group 1 - The total sales revenue of the 10 products is projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue for the first three quarters of 2025 [1] - The number of selected products represents 40% of the total number of formulations in the company's formulation segment [1] - The results of the selection process are expected to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] Group 2 - There is uncertainty regarding the signing of the procurement agreement and the execution of sales [1]

Core Viewpoint - Meinuohua's subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., is participating in the national organized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The company is involved in the bidding for the continuation of procurement for drugs that are part of the first to eighth batches of the national organized procurement agreements that have expired [1] - The expected selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] Group 2: Procurement Timeline - The results of the procurement selection are anticipated to be implemented by the end of March 2026 [1] - The procurement cycle for the selected drugs will last from the actual execution date of the selection results until December 31, 2028 [1] Group 3: Procurement Prioritization - During the procurement cycle, medical institutions will prioritize the use of the drugs selected in this continuation procurement and ensure the completion of the agreed procurement volume [1]